Research: Breast Cancer Drug Fulvestrant Appears More Effective in the Presence of CK8 and CK18

by Rajshri on  March 12, 2010 at 4:54 PM Cancer News
  •   Print
  •   Share
  •   Comments
  •  Text 
Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy that women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins.

Fulvestrant appeared to exert maximum anti-cancer effects in vitro when cells produced normal or elevated quantities of the cytokeratins CK8 and CK18, structural proteins that help give the nucleus its shape.

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been established in previous reports. The present study confirms fulvestrant's binding relationship to ER-alpha, while also showing two other proteins, cytokeratins 8 and 18, can strongly enhance fulvestrant's anti-estrogenic activity. Testing for the presence of these three proteins, and perhaps many others, could help doctors decide whether fulvestrant should be prescribed to their patients.

"We need an effective panel of markers that inform physicians about what treatment options will be most beneficial to patients," said Medical Sciences Program Bloomington cancer biologist Kenneth Nephew, who led the study. "These three gene products should be investigated further to determine whether they should be included in that panel."

Medical Sciences Program Bloomington is a division of the IU School of Medicine. Nephew is a professor of cellular and integrative physiology, and obstetrics and gynecology.

"Normal" breast cancer cells can grow faster in the presence of estrogen, a hormone. Estrogen attaches to receptors embedded in the cancer cell, such as ER-alpha in the cytoplasm and nucleus. The estrogen-ER complex can then act to turn on genes or amplify their expression. Not all cancer cells are responsive to estrogen, however, or to fulvestrant, which counteracts estrogen's effects.

Page 1 Page 1 | 2  Next
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
Quiz on Cancer
Looking for information on cancer? Go through medindia's Cancer quiz.
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Cancer
Complete Medindia Resources
News Categories:  
Vision Health Center

Cancer Related News

» Cardio-Pulmonary Function can be a Strong Indicator for Survival Chances of Breast Cancer Patients » Post Surgery Will the Tumour Return? New Breast Cancer Test to Predict Exactly
» Scientists Develop Compound That Triggers Cancer Cell Death » Iraqi National Hopes to Find Affordable Treatment for His Cancer in India
» New Technique can Help Doctors Detect Pancreatic Cancer » Colorectal Cancer Risk Factors Probed
» Breast MRI 'Better Than Clinical Approach for Predicting Chemotherapy's Efficiency' » No Need for PSA-Based Screening for Prostate Cancer: Task Force
Read More >>